ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia.

Maria R Baer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.